The Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI)1 trial, the only trial to show a mortality benefit related to glycaemic control post AMI, however recruited people with or without known diabetes and glucose > 11mmol/L peri-AMI, and the subsequent DIGAMI 2 trial enrolled participants with known diabetes, or glucose > 11mmol/L. This evidence concerns the gene INS and acute myocardial infarction.